BIRC5 and familial pancreatic carcinoma: Sherman et al. observed that calcipotriol treatment inhibits the protumoral activity of CAFs by reducing CAF-induced expression of genes involved in proliferation, survival, EMT, or chemoresistance (CXCL1, CCND1, CDK1, SHH, BIRC5, and AURKB) in pancreatic cancer cells (MIAPCa-2) [20].